发明名称 |
Process to control particle size |
摘要 |
A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process; passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters; optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage; and collecting a pharmaceutical substance with a median particle size greater than 10 μm and with a narrow, reproducible distribution of median particle sizes. |
申请公布号 |
US9034381(B2) |
申请公布日期 |
2015.05.19 |
申请号 |
US200612093045 |
申请日期 |
2006.11.10 |
申请人 |
Alphapharm Pty Ltd |
发明人 |
Mooney Brett Antony;Keramidas Panagiotis (Peter) |
分类号 |
A61K9/14 |
主分类号 |
A61K9/14 |
代理机构 |
|
代理人 |
|
主权项 |
1. A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of:
passing an initial feedstock of the pharmaceutical substance through a first stage of the multi-stage particle size reduction process, the first stage having a first set of particle size control parameters to obtain a further feedstock for at least a second stage of the multi-stage particle size reduction process; passing the further feedstock through the second stage of the multi-stage particle size reduction process, the second stage having a second set of particle size control parameters to obtain a pharmaceutical substance with a reduced median particle size and narrower distribution of median particle size than the further feedstock; and collecting the pharmaceutical substance of the final stage of the multi-stage particle size reduction process with a median particle size greater than 10 μm and with a narrow reproducible distribution of median particle size,wherein at least 50% of the particles of the pharmaceutical substance of the final stage have a particle size deviating no more than between 1 μm and 10 μm from the median particle size. |
地址 |
Carole Park AU |